We explore the coordinated HTA networks involved in EUnetHTA, define the HTACG and the deliverables ...
Read moreOncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...
Read moreWe explore joint scientific consultations; what they mean and why they are important to manufacturer...
Read moreWe explore what the joint clinical assessment (JCA) is, its process and what future developments may...
Read moreWe've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...
Read moreUsing Early Access Programs (EAPs) to give patients with life threatening conditions access to medic...
Read moreAmong the most expensive therapies are gene therapies that show promise to transform inherited disor...
Read moreOur Market Access experts investigate what early access opportunities are available in China to enab...
Read moreThe provision of funding for Early Access Programmes is not ubiquitous. We explore which EU5 countri...
Read moreAlmost a decade after it's inception, what have we learned from the UK early access to medicines sch...
Read more